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A B S T R A C T
Objective: To compare women’s views about blood pressure (BP) control in CHIPS (Control of
Hypertension In Pregnancy Study) (NCT01192412).
Design: Quantitative and qualitative analysis of questionnaire responses.
Setting: International randomised trial (94 sites, 15 countries).
Population/sample: 911 (92.9%) women randomised to ‘tight’ (target diastolic blood pressure, 85 mmHg)
or ‘less tight’ (target diastolic blood pressure, 100 mmHg) who completed questionnaires.
Methods: A questionnaire was administered at 6–12 weeks postpartum regarding post-discharge
morbidity and views about trial participation. Questionnaires were administered by the site co-
ordinator, and contact was made by phone, home or clinic visit; rarely, data was collected from medical
records. Quantitative analyses were Chi-square or Fisher’s exact test for categorical variables, mixed
effects multinomial logistic regression to adjust for confounders, and p < 0.001 for statistical
signiﬁcance. NVivo software was used for thematic analysis of women’s views.
Main outcome measures: Satisfaction, measured as willingness to have the same treatment in another
pregnancy or recommend that treatment to a friend.
Results: Among the 533 women in ‘tight’ (N = 265) vs. ‘less tight’ (N = 268) control who provided
comments for qualitative analysis, women in ‘tight’ (vs. ‘less tight’) control made fewer positive
comments about the amount of medication taken (5 vs. 28 women, respectively) and intensity of BP
monitoring (7 vs. 17, respectively). However, this did not translate into less willingness to either have the
same treatment in another pregnancy (434, 95.8% vs. 423, 92.4%, respectively; p = 0.14) or recommend
that treatment to a friend (435, 96.0% and 428, 93.4%, respectively; p = 0.17). Importantly, although
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate /e jo g rb* Corresponding author at: Maternal Medicine, St. George’s, University of London, Cranmer Terrace, Room J0.27, London SW17 0RE, United Kingdom.
E-mail address: LMagee@sgul.ac.uk (L.A. Magee).
1 The members of the CHIPS Study Group is listed in Table S1 of Appendix A.
http://dx.doi.org/10.1016/j.ejogrb.2016.07.509
0301-2115/ 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
M. Vidler et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 206 (2016) 105–113106satisfaction remained high among women with an adverse outcome, those in ‘tight’ control who suffered
an adverse outcome (vs. those who did not) were not consistently less satisﬁed, whereas this was not the
case among women in ‘less tight’ control among whom satisfaction was consistently lower for the CHIPS
primary outcome (p < 0.001), severe hypertension (p  0.01), and pre-eclampsia (p < 0.001).
Conclusions: Women in ‘tight’ (vs. ‘less tight’) control were equally satisﬁed with their care, and more so
in the face of adverse perinatal or maternal outcomes.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
was an international randomised trial of ‘less tight’ [target diastolic
blood pressure (dBP) of 100 mmHg] vs. ‘tight’ control (target dBP of
85 mmHg) of non-severe non-proteinuric hypertension in preg-
nancy [1]. ‘Less tight’ (vs. ‘tight’) control was associated with no
beneﬁt or harm to the baby, in terms of the primary outcome of
perinatal loss or high level neonatal care for >48 h (31.4% vs.
30.7%), or the secondary outcome of serious maternal complica-
tions (3.7% vs. 2.0%). However, ‘less tight’ (vs. ‘tight’) control was
associated with maternal risk, in terms of more severe hyperten-
sion (40.6% vs. 27.5%, p < 0.0001), platelet count <100  109/L
(4.3% vs. 1.6%, p < 0.05), and elevated liver enzymes with
symptoms (4.3% vs. 1.8%, p < 0.05). Although ‘less tight’ control
did not signiﬁcantly decrease rates of birth weight <10th centile
(16.1% vs. 19.8%), the differential rate of 3.7% may be interpreted by
some clinicians to be of potential clinical importance.
On balance, ‘tight’ control of non-severe pre-existing or
gestational hypertension in pregnancy appears to be the prudent
clinical approach. If a negative impact on fetal growth were true,
there was no evidence that this translated into a negative effect on
death or illness for the baby, as reﬂected by the CHIPS primary
outcome for which the trial was adequately powered. However, as
pregnant women are known to be reluctant to take medication in
pregnancy, clinicians may be reluctant to prescribe ‘tight’.
After a closed-meeting presentation of the CHIPS results to
investigators, more of them indicated that they would recommend
‘tight’ control (32, 45.7%) rather than ‘less tight’ control (6, 8.6%),
but a signiﬁcant number (30, 42.9%) were undecided and indicated
that they would seek women’s views before making their
recommendation.
In order to further inform clinicians about ‘tight’ (vs. ‘less tight’)
control, we extend the ﬁndings of the main trial by exploring the
views of women who were assigned to each type of BP control and
completed a postpartum questionnaire.
Materials and methods
CHIPS was a pragmatic, open, multicentre, international RCT
(ISRCTN 71416914; NCT01192412) [1]. It was approved by the
Research Ethics Board at the University of British Columbia as the
co-ordinating centre and at all study sites.
The protocol is available on-line at nejm.org. In brief, women at
14+0–33+6 weeks gestation with non-proteinuric pre-existing or
gestational hypertension, ofﬁce diastolic BP (dBP) 90–105 mmHg
(or 85–105 mmHg if on antihypertensives) and a live fetus were
randomised to ‘less tight’ control (target dBP 100 mmHg) or ‘tight’
(target dBP 85 mmHg). The composite primary outcome was
pregnancy loss or high level neonatal care for >48 h in the ﬁrst 28
days of life, and the secondary outcome, serious maternal
complications before 6 weeks postpartum. Outcomes were
compared between groups using logistic regression adjusted for
key prognostic factors.
This report is focussed on information collected by site co-
ordinators who were not responsible for direct patient care andwho had health sciences backgrounds and CHIPS-speciﬁc training.
Co-ordinators administered a structured postpartum question-
naire designed to: (i) collect information about potential post-
discharge maternal or neonatal morbidities in the 6 weeks
following birth for the mother, or 28 days of life for the baby,
whichever was later, that may contribute to the primary or
secondary outcomes; and (ii) explore maternal views about trial
participation. The questionnaire was completed by contacting all
CHIPS participants at 6–12 weeks postpartum (or 36 weeks
corrected gestational age for preterm babies, whichever was later),
by telephone, home or clinic visit, as appropriate for the centres; if
this was not possible, the co-ordinator contacted the woman’s
medical practitioner and/or reviewed medical records in order to
inform the primary and secondary outcomes (but not the
satisfaction component of the questionnaire).
Women’s views about trial participation were explored by two
standard questions: willingness to have the same treatment again
in a future pregnancy, and willingness to recommend the same
treatment to a friend) [2,3]. Women were invited to provide
comments after each question, as well as any other additional
comments that they wished to share. All responses were recorded
by co-ordinators at the time of interview, and subsequently
entered verbatim in English into the study database for analysis.
Quantitative analysis of the questionnaire was by Chi-square or
Fisher’s exact test as appropriate for categorical variables, with
p < 0.001 considered to be statistically signiﬁcant as speciﬁed a
priori by the CHIPS protocol.
Using mixed effects multinomial logistic regression, we
simultaneously estimate the odds ratio (OR) of ‘deﬁnitely yes’
vs. ‘probably/deﬁnitely not’ and ‘probably yes’ vs. ‘probably/
deﬁnitely not’ for ‘less tight’ vs. ‘tight’ control. The p value is against
the alternative hypothesis that at least one of these ORs is not equal
to 1. In the ﬁrst analysis as in the primary CHIPS analysis [1], we
adjusted for hypertension type, previous severe hypertension, use
of any antihypertensive therapy at randomisation, gestational
diabetes, weeks of gestation at randomisation, and centre (as
random effect). In an additional analysis, we also adjusted for
ethnicity, region, and perinatal mortality ratio of the recruiting
country to account for potential cultural differences in women’s
views.
NVivo qualitative research software (Version 10, 2012, QSR
International, Doncaster Victoria, Australia) was used to organise,
analyse, and interpret women’s free text responses. A thematic
analysis approach was used for this study. This method is
frequently used to identify patterns in large data sets so that
relevant patterns can be explored in-depth [4]. Data were coded
and stored as nodes that were subsequently used to explore similar
and disparate themes that either were speciﬁed a priori or emerged
during analysis (Panel 1). The ﬁrst stage of analysis included a ‘start
list’ of codes; these initial themes reﬂected the expected responses.
Subsequently, themes were added, combined and split to better
represent the respondents’ views that did not reasonably ﬁt into an
a priori thematic category. All data were coded by one researcher
(MV), a public health researcher with extensive experience in
qualitative analyses speciﬁcally within the hypertensive disorders
of pregnancy. Thematic categories were reviewed by study
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Panel 1. A priori and data driven theme categories for analysis of maternal responses to CHIPS postpartum questionnaire.
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themes. Respondents were classiﬁed to allow for analysis of the
qualitative ﬁndings according to: allocation to ‘less tight’ or ‘tight’
BP control, response to each of the maternal satisfaction questions,
and occurrence of each of the following adverse outcomes: primary
perinatal, secondary maternal, severe maternal hypertension, pre-
eclampsia, delivery at <34 weeks, and delivery at <37 weeks.
Results
There were 987 women randomised in CHIPS to ‘less tight’
(N = 497) or ‘tight’ control (N = 490) and included in the analyses
[1]. For the 981 women with data for the primary and secondary
outcomes (493 in ‘less tight’ and 488 in ‘tight’ control), an
additional 10 (5 vs. 5, respectively) were lost to follow-up for the
postpartum questionnaire after delivery, resulting in completedTable 1
Postpartum questionnaire completion for the 981 women in CHIPS (N (%) women or m
Respondents by any method 
Missing 
Time after delivery questionnaire completed (week) 
Method of questionnaire completionb
Telephone 
Personal interview 
Information obtained (in whole or part) from medical records or maternity care pr
Missing 
a Using Chi-square.
b Responses are not mutually exclusive.postpartum questionnaires for maternal and neonatal morbidity
for 971 (99.0%) women (Table 1). The primary perinatal outcome
(perinatal loss or high level neonatal care for >48 h) was informed
by the postpartum questionnaire in 25 (8.2%) babies (15/150 in
‘tight’ and 10/155 in ‘less tight’) and the secondary maternal
outcome in 5 (17.9%) women (4/10 in ‘tight’ and 1/18 in ‘less tight’).
Postpartum questionnaires were completed by mothers at a
median of about 8 weeks postpartum. Most questionnaires were
completed by telephone interview. In 60 (6.2%) women (30 in ‘less
tight’ and 30 in ‘tight’ control), questionnaires were completed
entirely by use of medical records, 52 because they were not
contactable, and 8 because of stillbirth or neonatal death that made
the co-ordinators uncomfortable contacting the women (Table S2).
As such, there were 911 postpartum questionnaires (from 92.9% of
women in the primary analysis) with data informative for the
maternal satisfaction and views analyses presented in this paper.edian [IQR], as appropriate).
‘Less tight’ control
N = 493
‘Tight’ control
N = 488
pa
488 (99.0%) 483 (99.0%) 1.00
5 5
8.29
[6.57; 11.57]
8.00
[6.71; 10.57]
0.55
309 (62.7%) 287 (58.8%) 0.21
158 (32.0%) 166 (34.0%) 0.51
ovider 43 (8.7%) 41 (8.4%) 0.86
5 5
Table 2
Women’s views about participation in CHIPS for 911 respondents to maternal satisfaction questions (N (%) women).
‘Less tight’ control
(N = 458)
‘Tight’ control
(N = 453)
Unadjusted analysis Adjusted
analyses
pa pb pc
Women willing to have the same treatment in another pregnancy
Respondents (N women) 454 (99.1%) 452 (99.8%)
Provided no answer 4 (0.9%) 1 (0.2%)
Deﬁnitely yes 309 (67.5%) 307 (67.8%) 0.18 0.15 0.14
Probably yes 114 (24.9%) 127 (28.0%)
Probably NOT 22 (4.8%) 15 (3.3%)
Deﬁnitely NOT 9 (2.0%) 3 (0.7%)
Provided further comments for qualitative analysis 268/454 (59.0%) 265/452 (58.6%)
Would recommend the same treatment to a friend
Respondents (N women) 455 (99.3%) 453 (100%)
Provided no answer 3 (0.7%) 0
Deﬁnitely yes 296 (64.6%) 281 (62.0%) 0.27 0.17 0.17
Probably yes 132 (28.8%) 154 (34.0%)
Probably NOT 24 (5.2%) 16 (3.5%)
Deﬁnitely NOT 3 (0.7%) 2 (0.4%)
Provided further comments for qualitative analysis 207/455 (45.5%) 213/453 (47.0%)
Respondents to one/both questions who chose to accept
the invitation to provide other comments
241/455 (53.0%) 219/453 (48.3%)
a Using Fisher’s exact test.
b Adjusted for hypertension type, previous severe hypertension, use of antihypertensive therapy at randomisation (yes/no), gestational diabetes at randomisation, weeks
of gestation at randomisation, and centre (as random effect) as in the main CHIPS adjusted analysis [1].
c Adjusted for hypertension type, previous severe hypertension, use of antihypertensive therapy at randomisation (yes/no), gestational diabetes at randomisation, weeks of
gestation at randomisation, and centre (as random effect) as in the main CHIPS adjusted analysis [1]. In addition to ethnicity, region and perinatal mortality ratio of the
recruiting country to account for potential cultural differences in women’s views.
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Table 2 presents the women’s views about their participation
the CHIPS Trial, from 911 respondents to the maternal satisfaction
questionnaire. Just over half of the women (i.e., 268/455 in ‘less
tight’ and 265/453 in ‘tight’ control) provided additional qualita-
tive comments. The vast majority of women in ‘tight’ (and ‘less
tight’) control were satisﬁed with their care, as measured by
willingness to either have the same treatment in another
pregnancy and highlighted in grey in Table 2 (92.4% in ‘less tight’
vs. 95.8% in ‘tight’ control) or recommend the same treatment to a
friend (93.4% vs. 96.0%, respectively).
Table 3 presents responses according to trial outcomes for all
but the CHIPS secondary outcome for which there were too few
events (N = 28) to allow for meaningful interpretation. Overall,
more than 80% of women reported being satisﬁed with their care,
regardless of their allocated group or pregnancy outcome;
however, women in ‘less tight’ control with an adverse outcome
(vs. those without) appeared to be less satisﬁed than women in
‘tight’ control who had an adverse outcome (vs. those without).
Among women who received ‘less tight’ control, those with an
adverse outcome (vs. those without) were signiﬁcantly less
satisﬁed (according to willingness to have the same treatment
in a future pregnancy and recommend treatment to a friend) for all
outcomes other than birth weight <10th centile. Among women in
‘tight ‘control, women with an adverse outcome (vs. those without)
were less willing to have the same treatment in a future pregnancy
for the CHIPS primary outcome and pre-eclampsia, but satisfaction
measured by recommending treatment to a friend was not
signiﬁcant for any outcome.
Qualitative analyses according to ‘less tight’ vs. ‘tight’ control and
satisfaction with care
Following completion of the closed-ended questions; just over
half of women provided additional general comments following
the ﬁrst, ‘willingness’ question, and just under half commented
following the second ‘recommend to a friend’ question (Table 2).The ﬁnal list of 18 themes used for qualitative analysis included
ﬁve themes driven by the data, four in research processes (i.e.,
comments about research staff, learning opportunity, quality of
study, and importance of research) and one in drivers of decision-
making (i.e., increased BP monitoring) (Panel 1).
Table 4 presents women’s themes according to ‘less tight’ vs.
‘tight’ control. Within each treatment group, responses according
to whether women were willing to have the same treatment in a
future pregnancy (as a measure of satisfaction), and then whether
the comments were positive (e.g., worry) or negative (e.g.,
reassurance) within that theme are presented in Table S3.
(Responses for the satisfaction question of ‘would recommend
treatment to a friend’ were similar and are presented in Appendix
Table S4.) In ‘tight’ (and ‘less tight’) control groups, most themes
were commented on positively. Women’s statements usually
related to processes of care (especially extra health care provider
care and quality of care), and less frequently, to ‘drivers of decision-
making’, followed by research-processes and outcomes.
With regards to process of care, comments reﬂected the
importance of one-to-one personalised attention (e.g., ‘‘kept a close
eye on me throughout my pregnancy’’, ‘less tight’) and the feeling
that the quality of care was better due to participation in the trial
(e.g., ‘‘because I seemed to be looked after better’’, ‘tight’). With
regards to the themes related to delivery of care and how the
research was conducted, women expressed that the trial enabled
them and their families to learn from the experience, as research staff
answered questions and explained the condition and procedures
thoroughly (e.g., ‘‘everything was explained to me, I understood
everything’’, ‘tight’ control). The information led some women to
become more involved in their health (e.g., ‘‘made me more
involved/compliant with my BP management’’, ‘tight’ control).
With regards to ‘drivers of clinical decision-making’, women in
‘tight’ control felt safe (e.g., ‘‘I feel more reassured about my
health, my pregnancy, and my baby’’, ‘tight’) and positively about
the BP level achieved, as did women in ‘less tight ‘control (e.g., ‘‘my
mind was at ease about not taking anything and that I was safe
on the trial’’, ‘less tight’; ‘‘I felt that my blood pressure was well
controlled’’, ‘less tight’). Women in ‘tight’ (vs. ‘less tight’) control
Table 4
Theme categories mentioned by women when asked about willingness to have the same treatment in another pregnancy.a
Theme ‘Less tight’ (N = 268) ‘Tight’ (N = 265)
Pos Neg Pos Neg
Process of care
Extra health care provider attention 63 1 60 1
Quality care 60 2 55 0
Quality of treatment 17 5 16 3
Research processes
Comments about research staff 20 1 21 0
Play role in research & help othersb 23 0 16 0
Learning opportunityb 11 0 26 0
Quality of study 14 1 14 0
Amount of work required 11 4 16 3
Importance of researchb 2 0 3 0
Drivers of decision-making
Feelings of safety (+) or worry () 23 5 22 3
Amount of medication 28 8 5 9
Blood pressure level achieved 11 14 11 6
Increased BP monitoring 17 1 7 1
Outcomes
Maternal outcomes 24 10 33 6
Infant outcomes 4 0 13 3
Other
Any/no problems 14 0 11 0
Planning for future pregnanciesc 8 0 7 0
Don’t knowc 3 0 6 0
a Results are presented according to randomised group (‘less tight’ vs. ‘tight’ control), willingness to have the same treatment in another pregnancy (‘yes’ or ‘no’), and
whether the comments made were positive or negative.
b These themes are positive by their nature.
c These themes are neither positive nor negative in nature.
Table 3
Satisfaction by outcome among women in ‘less tight’ (N = 488) vs. ‘tight’ control (N = 483).a
Theme ‘Less Tight’ control (N = 488) ‘Tight’ control (N = 483)
Adverse outcome No adverse outcome p Adverse outcome No adverse outcome pb
CHIPS primary outcome N = 151 N = 337 N = 148 N = 335
Willing to have treatment in future pregnancy 0.005* 0.02*
Yes 126 (83.4%) 305 (90.5%) 127 (85.8%) 308 (91.9%)
No 17 (11.3%) 15 (4.5%) 10 (6.8%) 8 (2.4%)
Missing 8 17 11 19
Recommend treatment to a friend 0.002* 0.41
Yes 127 (84.1%) 309 (91.7%) 130 (87.8%) 306 (91.3%)
No 16 (10.1%) 12(3.6%) 7 (7.5%) 11 (5.4%)
Missing 8 16 11 18
Birth weight <10th centile N = 77 N = 411 N = 95 N = 388
Willing to have treatment in future pregnancy 0.37 0.14
Yes 68 (88.3%) 363 (88.3%) 83 (87.3%) 352 (90.7%)
No 7 (9.1%) 25 (6.1%) 6 (6.3%) 12 (3.1%)
Missing 2 23 6 24
Recommend treatment to a friend 0.43 0.39
Yes 69 (89.6%) 367 (89.3%) 85 (89.5%) 351 (90.5%)
No 6 (7.8%) 22 (5.3%) 5 (5.3%) 13 (3.4%)
Missing 2 22 5 24
Severe hypertension N = 197 N = 291 N = 131 N = 352
Willing to have treatment in future pregnancy 0.004* 0.08
Yes 170 (86.3%) 261 (89.7%) 113 (86.3%) 322 (91.5%)
No 21 (10.6%) 11 (3.8%) 8 (6.2%) 10 (2.8%)
Missing 6 19 10 20
Recommend treatment to a friend 0.01* 0.93
Yes 173 (87.8%) 263 (90.4%) 117 (89.3%) 319 (90.6%)
No 18 (9.1%) 10 (3.4%) 5 (3.8%) 13 (3.7%)
Missing 6 18 9 20
Pre-eclampsia N = 237 N = 251 N = 221 N = 262
Willing to have treatment in future pregnancy 0.0005* 0.03*
Yes 200 (84.4%) 231 (92.0%) 193 (87.3%) 242 (92.4%)
No 25 (10.5%) 7 (2.8%) 13 (5.9%) 5 (1.9%)
Missing 12 13 15 15
Recommend treatment to a friend 0.0002* 0.92
Yes 202 (85.2%) 234 (93.2%) 199 (90.0%) 237 (90.5%)
No 23 (9.7%) 5 (2.0%) 8 (3.6%) 10 (3.8%)
Missing 12 12 14 15
a Satisfaction was explored according to whether women were willing to have the same treatment in a future pregnancy (yes/no), or recommend the same treatment to a
friend in her pregnancy (yes/no).
b p value by Chi-square or Fisher’s Exact Test, as appropriate.
* These results were signiﬁcant with a p-value.
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medication taken (5 vs. 28, respectively) and the level of BP
monitoring (7 vs. 17, respectively), but more positive comments
regarding outcomes for both mother (33 vs. 24, respectively) and
baby (13 vs. 4, respectively).
Most negative comments were made by women who were not
willing to have the same treatment again in a future pregnancy or
recommend that treatment to a friend (Table S3). Women were
worried about having taken too much medication in ‘tight’ control
(e.g., ‘‘did not like having high doses of medication’’) or too little
medication in ‘less tight’ control (e.g., ‘‘being off meds made her
feel anxious and concerned [about] stroke or heart attack’’).
Women in ‘tight’ control may have less frequently expressed
concerns about BP level achieved (under drivers of clinical
decision-making), and outcomes compared with women in ‘less
tight’ control, as illustrated by comments such as, ‘‘I cannot have
less tight control in the future as my last pregnancy was difﬁcult
in terms of blood pressure management’’ (‘less tight’), and ‘‘[I]
was not happy with having an abruption, wondering if being in
less tight group contributed’’ (‘less tight’).
Comment
Summary of results
In CHIPS, more than 90% of women in both ‘tight’ and ‘less tight’
control groups expressed satisfaction as reﬂected by a willingness
to have the same treatment in a future pregnancy or recommend
that treatment to a friend. Additional comments revealed that
women in both BP control groups had a positive research
experience and high regard for the quality of care received. This
ﬁnding likely reﬂects the high quality of care provided to women as
part of the CHIPS Trial.
In ‘tight ‘control, satisfaction remained high among women
with an adverse outcome, even in comparison with women
without an adverse outcome; this was not consistently true among
women in ‘less tight’ control. Qualitative analysis of comments
supported these ﬁndings, despite women in ‘tight’ control making
fewer positive comments about the amount of medication received
or the level of BP monitoring. This would suggest that preferences
to limit medication use and monitoring are not the primary drivers
of satisfaction overall or with outcomes. Nevertheless, some
women in both groups reported anxieties related to treatment of
their BP during pregnancy, highlighting the importance of
psychological support in pregnancy and postpartum.
Strengths and weaknesses
Strengths of this study include its large numbers, randomisa-
tion to ‘less tight’ vs. ‘tight’ BP control (such that the two groups of
women should have differed only by the type of BP control that
they received), high response rate, and inclusion of open-ended
questions that allowed participants to describe their feelings and
explain their responses. Also, the qualitative and quantitative
ﬁndings are from the same individuals, so the former results can be
used to support the latter.
Weaknesses include that the postpartum questionnaire was
administered by the CHIPS trial co-ordinators to whom respon-
dents knew from data collection throughout the trial; although
women may have felt uncomfortable expressing negative feelings
regarding their treatment, the co-ordinators were not in charge of
their care. There were small numbers of women in some thematic
groups, making inferences difﬁcult. Given the number of countries
involved (N = 15) and languages (N = 9), it was not possible to
either explore responses by region/country of recruitment or
conduct the thematic analysis ﬁrst in the original language whichmay have avoided potential error introduced by translation
followed by thematic analysis in English. Satisfaction may have
been best explored using scales rather than by asking about
willingness to have the same treatment again or recommend it to
a friend, but CHIPS was a large, international trial, and issues of
language, culture and cost inﬂuenced our decision to go with
simplicity. Postpartum questionnaires were not completed for 8/
25 women who suffered perinatal losses; in this minority of
cases, study co-ordinators did not feel comfortable contacting
participants (as outlined in the CHIPS protocol) to explore
satisfaction of the CHIPS Trial. Although we respected their
views, and the number of women affected was small, our
decision may have skewed the results. Finally, the views
presented here may not be generalisable to hypertensive
pregnant women in general.
Comparison with the published literature
Our data from the main CHIPS Trial document similar
satisfaction rates to those reported by women who participated
in the CHIPS Pilot Trial, in which more than 90% of women were
satisﬁed with their BP management and care, regardless of
allocation to ‘less tight’ or ‘tight’ BP control [5]. This was true
despite being very involved in management of their BP, as in the
main CHIPS Trial; women were expected to know the dBP goal to
which they had been randomised, and to carry a diary in which all
BP measurements were to be recorded. Our data from the main
CHIPS Trial go further by collecting and qualitatively analysing
additional comments that women were invited to provide.
Comments from women assigned to ‘tight’ (or ‘less tight’) control
most commonly related favourably to process of care. This is
consistent with knowledge that women’s involvement in their
care, the quality of the caregiver–patient relationship, and the
amount of support from caregivers all inﬂuence women’s
evaluation of care, regardless of setting [6,7]. We were unable to
identify additional published literature on women’s views about
their BP management per se, in distinction to their preferences for
home BP measurement [8], outpatient (vs. inpatient) care [9], and
adequate information about prognosis [10]. These studies indicate
the preference for outpatient monitoring, similar to the care
provided for the majority of women in CHIPS (i.e., 84.0% vs. 83.2%
in ‘less tight’ vs. ‘tight’ control, respectively) [8,9]. However,
numerous studies exploring patient satisfaction in RCTs have
reported similar drivers in willingness to participate: personal
clinical beneﬁt, a duty to help others, the importance of
contributing to research, increased specialist attention, learning,
a good rapport with the research team, clinical reassurance, and
perceptions of treatment [11–13].
A stakeholder analysis would be ideal to seek the views of
clinicians regarding ‘tight’ and ‘less tight’ control of BP, taking into
account primary and secondary analyses of CHIPS data, including
those of women’s views.
Conclusion
This qualitative study extends the ﬁndings of the main CHIPS
Trial by detailing the individual experiences of women who
received ‘less tight’ and ‘tight ‘control. Women in ‘tight’ control
were satisﬁed with their care, even in the face of adverse outcomes.
Clinicians prescribing ‘tight’ BP control in pregnancy should feel
reassured by this information.
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